Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Karp

Showing results (191-200 of 214) with videos related to

Pageof 22
Sort By:
The Oncologist|March 14, 2020
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like PhenomenonShaheen Khan, Mitchell S von Itzstein, Rong Lu, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|November 13, 2009
Sequence feature variant type (SFVT) analysis of the HLA genetic association in juvenile idiopathic arthritisGlenys Thomson, Nishanth Marthandan, Jill A Hollenbach, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical FeaturesMelissa E Munroe, Kendra A Young, Diane L Kamen, et al.
Biomolecules|April 30, 2025
Mapping Current Studies of tRNA Fragments onto Disease LandscapeSathyanarayanan Vaidhyanathan, MacKenna Durbin, Adesupo A Adetowubo, et al.
Lupus Science & Medicine|November 28, 2025
Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activityMelissa E Munroe, Kendra Young, Rufei Lu, et al.
Arthritis Care & Research|January 25, 2017
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and ControlsTeresa Aberle, Rebecka L Bourn, Melissa E Munroe, et al.
The Oncologist|May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Annals of the Rheumatic Diseases|June 21, 2019
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individualsNeelakshi R Jog, Kendra A Young, Melissa E Munroe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 15, 2021
ReplyLauren A Henderson, Kevin G Friedman, Mary Beth F Son, et al.
Annals of the Rheumatic Diseases|June 11, 2016
Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosusKendra A Young, Melissa E Munroe, Joel M Guthridge, et al.
Pageof 22

Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
The Oncologist|March 14, 2020
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like PhenomenonShaheen Khan, Mitchell S von Itzstein, Rong Lu, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|November 13, 2009
Sequence feature variant type (SFVT) analysis of the HLA genetic association in juvenile idiopathic arthritisGlenys Thomson, Nishanth Marthandan, Jill A Hollenbach, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical FeaturesMelissa E Munroe, Kendra A Young, Diane L Kamen, et al.
Biomolecules|April 30, 2025
Mapping Current Studies of tRNA Fragments onto Disease LandscapeSathyanarayanan Vaidhyanathan, MacKenna Durbin, Adesupo A Adetowubo, et al.
Lupus Science & Medicine|November 28, 2025
Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activityMelissa E Munroe, Kendra Young, Rufei Lu, et al.
Arthritis Care & Research|January 25, 2017
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and ControlsTeresa Aberle, Rebecka L Bourn, Melissa E Munroe, et al.
The Oncologist|May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Annals of the Rheumatic Diseases|June 21, 2019
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individualsNeelakshi R Jog, Kendra A Young, Melissa E Munroe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 15, 2021
ReplyLauren A Henderson, Kevin G Friedman, Mary Beth F Son, et al.
Annals of the Rheumatic Diseases|June 11, 2016
Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosusKendra A Young, Melissa E Munroe, Joel M Guthridge, et al.
Pageof 22